LeonaBio, Inc. — fact timeline

LeonaBio, Inc. reported financial results for the quarter ended March 31, 2026.

“On May 7, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2026.”

LeonaBio, Inc. reported financial results for the year ended December 31, 2025.

“On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.”

LeonaBio, Inc.: Amended and restated bylaws to reflect the name change to LeonaBio, Inc (effective 2026-01-09).

“Additionally, effective January 9, 2026, the Board approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.”

LeonaBio, Inc.: Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc (effective 2026-01-09).

“Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.”

LeonaBio, Inc. entered into PIPE Securities Purchase Agreement with Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors valued at approximately $90 million (effective 2025-12-18).

“On December 18, 2025, Athira Pharma, Inc. (the “ Company ” or “ Athira ”) entered into a securities purchase agreement (the “ PIPE Securities Purchase Agreement ”) with a select group of investors, including Commodore Capital LP (“ Commodore ”), TCG Crossover Management LLC (“ TGCX ”), Perceptive Advisors (“ Perceptive ”) and other accredited investors”

LeonaBio, Inc. issued pre-funded warrants to purchase 8,816,684 shares of Common Stock; Series A warrants to purchase 23,031,494 shares; Series B warrants to purchase 21,259,842 shar of warrant to Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.349 per pre-funded warrant (including accompanying warrants); Series A exercise price $6.35 per share; Series B exercise price $7.62 per share.

“Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying”

LeonaBio, Inc. issued 5,356,547 shares of common stock to Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.35 per share.

“Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying”

LeonaBio, Inc. issued 21,259,842 shares of Common Stock of warrant to a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors.

“The PIPE Series B Common Warrants will have an exercise price of $7.62 per share payable on a cashless net exercise basis”

LeonaBio, Inc. issued 23,031,494 shares of Common Stock of warrant to a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors.

“The PIPE Series A Common Warrants will have an exercise price of $6.35 per share”

LeonaBio, Inc. issued 8,816,684 shares of Common Stock underlying pre-funded warrants of warrant to a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.349 per underlying share.

“Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying”

LeonaBio, Inc. issued 5,356,547 shares of common stock to a select group of investors, including Commodore Capital LP, TCG Crossover Management LLC, Perceptive Advisors and other accredited investors for $6.35 per share.

“Shares, the “ PIPE Shares ”). The purchase price for each PIPE Initial Share (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pre-Funded Warrant (including the accompanying PIPE Series A Common Warrants and PIPE Series B Common Warrants) is $6.349 per each underlying”

LeonaBio, Inc.: Amended certificate of incorporation to effect a 10-for-1 reverse stock split (effective 2025-09-17).

“On September 10, 2025, the Company filed a certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware to effect a 10-for-1 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share, effective as of 5:00 p.m., Eastern Time, on September 17, 2025 (the “Reverse Stock Split”).”

LeonaBio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“October 16, 2024 notifying the Company that, based on the closing bid price of the Company’s Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company had an initial compliance period of 180 calendar days, or until April 14, 2025, to regain compliance with t”

LeonaBio, Inc. announced a restructuring with charges of approximately $2.8 million (approximately 49 positions, representing approximately 70% of the Company’s workforce).

“priorities, including the continued development of ATH-1105. In connection with the Restructuring, the Company currently estimates it will incur one-time costs of approximately $2.8 million, consisting primarily of cash severance costs and termination benefits, which the Company expects to recognize in the third quarter of 2024. The Company expects to substantially”

LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.”

LeonaBio, Inc. reported financial results for the year ended December 31, 2023.

“On February 22, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.”

Hans Moebius changed role as Senior Scientific Advisor at LeonaBio, Inc..

“Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.”

LeonaBio, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 9, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.”

LeonaBio, Inc. reported financial results for quarter ended June 30, 2023.

“On August 10, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.”

LeonaBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-18 meeting.

“Proposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023. The following sets forth the results of the voting with respect to this proposal: For Against Abstain Broker Non-Votes 26,704,561 39,131 19,936 0”

LeonaBio, Inc. shareholders approved Election of Class III Directors at the 2023-05-18 meeting.

“Proposal No. 1 – Election of Class III Directors The stockholders elected the two candidates nominated by the Company’s Board of Directors (the “Board”) to serve as directors of the Company until the annual meeting of stockholders to be held in 2026 or until their successors are elected and qualified. The following sets forth the results of the voting with respect to each candidate: Nominees of the Board For Withhold Broker Non-Votes Kelly A. Romano 13,993,414 3,466,402 9,303,812 James A. Johnson 14,519,313 2,940,503 9,303,812”

Andrew Gengos was appointed as Chief Financial Officer and Chief Business Officer at LeonaBio, Inc..

“the Company’s board of directors (the “Board”) appointed Andrew Gengos as the Company’s Chief Financial Officer and Chief Business Officer, effective May 18, 2023.”

Glenna Mileson resigned as Chief Financial Officer at LeonaBio, Inc..

“Glenna Mileson, the Company’s Chief Financial Officer, resigned from her position as Chief Financial Officer on May 18, 2023 effective immediately.”

LeonaBio, Inc. reported financial results for the first quarter ended March 31, 2023.

“On May 11, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.”

LeonaBio, Inc. reported financial results for the year ended December 31, 2022.

“On March 23, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2022.”

LeonaBio, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and BTIG, LLC valued at maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement (effective 2023-01-06).

“On January 6, 2023, Athira Pharma, Inc, a Delaware corporation (the “Company”), entered into a Controlled Equity Offering Sales Agreement SM (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and BTIG, LLC (“BTIG” and together with Cantor, the “Agents” and each, an “Agent”).”

LeonaBio, Inc.: Amended and restated bylaws to comply with Rule 14a-19 and enhance advance notice procedures for stockholder proposals and nominations, along with other updates (effective 2022-11-15).

“On November 15, 2022, the board of directors (the “Board”) of Athira Pharma, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”) of the Company, effective immediately.”

LeonaBio, Inc. reported financial results for the third quarter ended September 30, 2022.

“Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the third quarter ended September 30, 2022 and reviewed recent clinical and corporate updates.”

Michael Panzara was appointed as director at LeonaBio, Inc..

“appointed Dr. Michael Panzara as a director of the Company, effective immediately.”

Grant Pickering was appointed as Director at LeonaBio, Inc..

“On January 27, 2022, the board of directors of Athira Pharma, Inc. (the “Company” or “Athira”), upon recommendation from the nominating and corporate governance committee of the Company’s board of directors (the “Board”), appointed Grant Pickering as a director of the Company, effective immediately.”